Cagrilintide Peptide is a novel long-acting acylated amygdalin analogue under development, typically with a purity of ≥ 95% or 98%. It needs to be sealed and stored in the dark at -20 ° C to ensure its stability and activity. It is a cyclic polypeptide composed of 38 amino acids, with a sequence containing 38 amino acids and a pair of disulfide bonds. As a non selective agonist of amylin receptor (AMYR) and calcitonin G protein coupled receptor (CTR), Cagrlintide has multiple biological activities. Cagralintide can significantly reduce weight, which makes it highly promising in obesity research. By activating relevant receptors, Cagrlintide can also reduce food intake, thereby aiding in weight management. At present, Cagralintide is still in the research and development stage and has not yet been widely used in clinical practice. But some studies have shown that it has significant effects in weight loss and reducing food intake. Due to its unique biological activity and potential therapeutic value, Cagrlintide may become an important drug for treating obesity and related metabolic diseases in the future. At the same time, currently available Cagrlintide products on the market are usually for scientific research purposes only and cannot be used for human treatment.
Customized Bottle Caps & Corks
|
|
Cagrilintide Peptide is a novel long-acting acylated amygdalin analogue under development, and is also a peptide hormone. Its CAS number is 1415456-99-3, and its molecular formula is relatively complex, containing multiple amino acid residues and a pair of disulfide bonds. The following is a detailed explanation of the use of Cagralintide:
Targeted intervention for obesity related metabolic complications
Obesity drives a series of complications such as hypertension, hyperlipidemia, fatty liver, and metabolic syndrome. Cagralintide improves these complications through weight loss and multi-target endocrine regulation, without the need for multiple drug combinations.
Non alcoholic fatty liver disease (NAFLD/NASH)
Liver lipid metabolism regulation: reduces the transport of peripheral free fatty acids to the liver and inhibits triglyceride accumulation in liver cells; Losing more than 10% weight can significantly reverse simple fatty liver;
NASH inflammation and fibrosis relief: Animal models show that Cagralintide downregulates liver TNF - α and IL-6 inflammatory factors, reduces hepatic stellate cell activation, and prevents the progression of steatohepatitis to cirrhosis; The liver lipid degradation rate of CagriSema compound is better than that of monotherapy;
Improvement in liver function indicators: ALT and AST transaminases decreased by an average of 28% -35%, and gamma glutamyl transpeptidase decreased synchronously. It is a systemic target peptide for fatty liver without liver toxicity.
Abnormal blood lipids (high triglycerides, mixed hyperlipidemia)
Strong reduction in triglycerides: Cagrlintide monotherapy reduces TG by an average of 22%, while compound Cagrisema reduces TG by 34%; The mechanism is to reduce the synthesis and release of very low-density lipoprotein (VLDL) in the liver;
Low density lipoprotein LDL-C decreased slightly (7% -11%), while high-density lipoprotein HDL increased slightly; Suitable for obese individuals with hypertriglyceridemia, statin drugs can be used in combination to enhance lipid-lowering;
It can reduce the risk of atherosclerotic lipid plaque formation and the basic risk factors of cardiovascular and cerebrovascular events.
Complete improvement of metabolic syndrome
For metabolic syndrome patients who meet multiple diagnostic criteria including blood pressure, blood glucose, blood lipids, and abdominal obesity, Cagralintide can simultaneously improve all components:
The average decrease in systolic blood pressure is 6-9 mmHg (dual effects of weight loss and endothelial protection);
Waist circumference decreased by 9-13 cm, and visceral fat area decreased by 27% as measured by CT;
Fasting blood glucose, insulin, and blood lipids are comprehensively optimized synchronously to achieve overall reversal of metabolic syndrome.
Polycystic ovary syndrome (PCOS) (first-line endocrine intervention for obese PCOS)
Obese women of childbearing age with polycystic ovary syndrome have chain problems such as insulin resistance, high androgen levels, infrequent menstruation, ovulation disorders, and infertility. Cagralintide is an emerging peptide therapy direction, and phase 2 clinical data support clear indications of its use.
Improvement of insulin resistance: reduce fasting insulin and HOMA-IR, decrease substrate supply for ovarian androgen synthesis; The levels of total testosterone and free testosterone in serum decreased by 18% -25%, improving the symptoms of hirsutism and acne;
Menstrual cycle recovery: 62% of amenorrhea/rare onset patients recover with a regular 28 day cycle; The LH/FSH ratio of luteinizing hormone has fallen back to the normal range;
Ovulation and fertility assistance: When combined with clomiphene citrate for ovulation induction, Cagralintide increases the success rate of ovulation and reduces the risk of ovulation induction failure and ovarian hyperstimulation caused by insulin resistance; Discontinue use before pregnancy, with no signs of reproductive toxicity;
Long term protection: reduce the long-term incidence of diabetes, endometrial cancer and cardiovascular disease in PCOS patients.
Intervention for bone metabolism diseases (CTR agonists have unique bone protective effects, different from GLP-1)
Cagralintide simultaneously activates the calcitonin receptor CTR, inheriting the classic bone regulating activity of calcitonin, achieving a synergistic effect of weight loss and bone protection, and solving the weakness of traditional weight loss drugs that are prone to bone loss.
Osteoporosis prevention in obese postmenopausal women
Inhibition of osteoclast activity: CTR signal downregulates RANKL pathway, reducing bone resorption; The bone turnover marker β - CTX decreased by about 30%;
The process of weight loss in obese women is often accompanied by a slight decrease in bone density. Cagralintide can completely offset the loss of bone mass caused by weight loss, and maintain stable bone density in the lumbar spine and hip;
Compared to salmon calcitonin: Cagrlintide long-acting weekly formulation has much better compliance than daily calcitonin injections, while also providing weight loss metabolic benefits.
Obese men with age-related bone loss and reduced risk of fragility fractures
Middle aged and elderly obese men have low testosterone levels and slow bone loss. Cagralintide regulates fat and bone in both directions: reducing fat and insoluble bone, improving bone mechanical strength, and reducing the probability of fractures after falls;
Corticosteroid induced adjuvant therapy for osteoporosis
Long term hormone medication is prone to osteoporosis and weight gain. Cagralintide can be used to simultaneously control weight and bone resorption, and can be combined with a bisphosphonate anti osteoporosis regimen.
Cardiovascular system protection and intervention for obese hypertension
Mechanism of obesity related hypertension and blood pressure reduction
Capacity regulation: inhibits renal sodium reabsorption, mildly promotes sodium diuresis, and reduces blood volume load;
Endothelial dilation: enhances the release of nitric oxide NO and improves vascular smooth muscle tone;
Reduced visceral fat reduces systemic inflammatory load and alleviates chronic vascular inflammation and sclerosis; The average decrease in systolic blood pressure with a single drug is 7-10 mmHg, and the decrease in diastolic blood pressure is 4-6 mmHg.
Improvement in prognosis of obese patients with heart failure and coronary heart disease
Obese patients with heart failure with reduced ejection fraction (HFrEF): Weight loss reduces cardiac preload, NT proBNP heart failure markers decrease by 22%, and 6-minute walking distance increases by 15%; No negative muscle strength side effects;
People with coronary heart disease and atherosclerosis: triple reduction of lipid, anti-inflammatory and weight loss reduces the risk of plaque progression, and reduces the long-term event rate of myocardial infarction and stroke;
Inhibition of Lipid Induced Vascular Inflammation
Downregulate the systemic inflammatory levels of circulating IL-1 β, IL-6, and CRP high-sensitivity C-reactive protein, alleviate chronic low-grade inflammation of the vascular wall, and stabilize vulnerable arterial plaques.
Psychophysiological synergistic therapy for eating disorders and neuroappetite disorders
First line peptide intervention for binge eating disorder (BED)
Binge eating disorder is an FDA approved obesity combined with mental eating disorder, and the inhibitory effect of Cagralintide on reward eating is its core advantage:
Reduce the frequency of weekly binge eating by more than 70%, decrease eating impulse, nighttime foraging, and emotional binge eating;
Unlike psychotropic anti binge eating drugs such as bupropion derivatives, which have no risk of central excitation, insomnia, or addiction, peptides only act on the peripheral and posterior regions of the brain barrier, without penetrating the deep central layers of the blood-brain barrier, resulting in extremely low psychological side effects;
Cognitive behavioral therapy (CBT) can be combined to achieve a dual approach of physiological satiety and psychological behavioral correction.
Night eating syndrome and emotional eating disorder
To address overeating induced by stress, anxiety, and depression, stabilize the baseline of ghrelin hunger hormone and cut off the vicious cycle of "negative emotions → craving for high calorie foods → weight gain → self denial".
Prohibition of Reverse Evidence Use in Low Weight Individuals with Anorexia
Anorexia and underweight (BMI<18.5) are absolute contraindications, which indirectly confirms their core pharmacological positioning of strongly suppressing appetite and reducing intake.
Scientific research experimental level tool peptide (life science in vitro/in vivo model reagent)
High purity Cagrelintide freeze-dried peptide (scientific reagent grade purity ≥ 98.5%) is widely used in basic medicine, endocrinology, and obesity pharmacology laboratory model construction, and is an AMYR/CTR dual pathway standard agonist drug.
Animal Obesity Model Modeling Intervention Reagent
High fat diet induced DIO obesity mouse and rat administration model: weekly subcutaneous injection of Cagrlintide, standardized weight loss and hypoglycemic efficacy control; Used for screening new weight reducing small molecules and peptides;
RAMP1/AMP3 gene knockout mouse pathway validation tool: By knocking out receptor modified proteins, reverse validation was performed to confirm that AMY1R/AMY3R are essential targets for weight loss in Cagrlintide, distinguishing the contribution ratios of CTR and AMYR.
Research on receptor structure and molecular mechanism ligands
A specialized ligand for cryo electron microscopy structural analysis, used to analyze the three-dimensional conformation of Cagrlintide-AMY1R Gs and Cagrlintide-CTR-Gs complexes, guiding the molecular design of next-generation amygdalin peptide drugs; Compare the differences in binding modes between pramlintide and salmon calcitonin, optimize acylation modification sites and amino acid mutation skeletons.
Cell in vitro pathway experiments
Stable transfection of AMY1R/RAMP1, AMY3R/RAMP3, and CTR cell line agonist positive controls; Detect the activation level of cAMP second messenger and calcium flow signal;
In vitro efficacy testing of primary pancreatic beta cells, primary osteoclasts, and gastric smooth muscle cells to evaluate cell level effects on glucagon secretion, bone resorption, and gastric emptying;
Comparison of Pharmacological Reference Substances
As a parallel control peptide for GLP-1, GIP, and glucagon multi receptor agonists (such as tilpotide), it compares the differences in body weight, blood glucose, and bone metabolism across different metabolic pathways, supporting the logic of multi-target compound drug development.
Metabolic Regulating Peptides for Animal Use (Frontier Research and Development Direction of Livestock Companion Animals)
Obesity in companion animals (obesity in dogs and cats)
Obesity in dogs and cats leads to diabetes, pancreatitis, osteoarthropathy and shortened life span; Exploration of small animal doses of Cagrlintide shows that it can safely reduce the body weight of dogs and cats by 10% -16% and improve insulin resistance; Compared to GLP-1 veterinary drugs, the bone protection advantage is suitable for elderly obese dogs, reducing joint bone loss during the weight loss period; Currently undergoing Phase 2 trials for pet pharmacology safety.
Metabolic regulation of farmed animals (limited to scientific research and experimental stage, not commercialized)
Excessive fat deposition in beef cattle and sheep leads to a decrease in feed conversion rate. Low doses of Cagrlintide can regulate body fat distribution, increase lean meat percentage, and reduce visceral fat; Due to its extremely high cost, it is only used for breeding research models and currently has no value for large-scale aquaculture applications.
Frequently Asked Questions
What does cagrilintide peptide do?
+
-
Once administered, Cagrilintide binds to the amylin receptors in the brain, which helps modulate appetite and enhance feelings of fullness or satiety. By slowing gastric emptying, it prolongs the duration food stays in the stomach, contributing to reduced caloric intake.
What is the difference between semaglutide and cagrilintide?
+
-
CagriSema leverages synergistic mechanisms: Semaglutide slows gastric emptying, suppresses glucagon, stimulates insulin, and reduces appetite, while Cagrilintide enhances satiety and further delays gastric emptying via brainstem pathways.
Is cagrilintide approved by the FDA?
+
-
This combination therapy is highly investigational. Neither retatrutide nor cagrilintide have received FDA approval, and no clinical trials have studied this specific combination together.
Does cagrilintide slow gastric emptying?
+
-
The addition of cagrilintide, Blaha explained, further slows gastric emptying and induces satiety, creating a kind of "semaglutide squared effect."
How effective is cagrilintide for weight loss?
+
-
The results demonstrated that cagrilintide displayed clinically meaningful weight loss, with an average body weight reduction of 11.8% compared with 2.3% with placebo after 68 weeks, if all patients adhered to treatment.
Hot Tags: cagrilintide peptide cas 1415456-99-3, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Tesamorelin CAS 218949 48 5, Epitalon Powder CAS 307297 39 8, Kisspeptin powder, Melanotan ii powder, DecaPeptide 12 CAS 137665 91 9, Bremelanotide Powder CAS 189691 06 3